As requested by our invited Chinese pharma and investors, we are now inviting companies that meet their partnering/investment objective to China Focus@BIO Philadelphia.

All applications will be promptly reviewed by the program committee. The selected companies are entitled to a free registration ($995 value) of China Focus event and will provide 8-minute pitch, followed by 1:1 meeting with the guests who express interest in your assets, at our designated VIP partnering areas.

The private pitch is invitation only and the audiences are pharma senior executives and prestigious investors, exclusively. You may find the list as follows and more audiences are joining us.

 

Featured Guests

Fosun Pharma: Fosun Pharma regards innovation, research and development as the core driving factor of development and established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform. Currently, Fosun Pharma continues to focus on therapeutic areas including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system and anti-infection.
Representative: 
Lily Zou, CEO, Fosun Pharma US
Larry Cai, Executive Director, Business Development
Northern Light Venture Capital: A leading venture capital firm targeting early stage opportunities of innovation in Healthcare, TMT and Advanced Technology. It is established in 2005 and today it has $4.5 billion dollar managed capital. Leveraging successful investing and entrepreneurial expertise in both China and the United States, the NLVC team looks for partnering with world class entrepreneurs to build world class companies.
Representative:
Cynthia Cai, Senior Advisor
Sanofi: Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Representatives: 
Jenny J. Wang, Director Oncology External Innovation, Global Business Development & Licensing
Julie Carnis, Associate Director China & EM

Luye Pharma: Luye pharma is an international pharmaceutical company dedicated to the R$D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe. Luye Pharma has reached a high level international standard in advanced drug delivery technologies such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.
Representative:
Herwig Janssen, VP, Licensing & Acquisitions Emerging Markets

 

FC Capital: FC Capital is a cross-border VC/PE fund specialized in healthcare and life science investments. The team operates from its headquarters in Shanghai with additional offices in Taipei and Boston. FC seeks to invest in early stage assets in biopharmaceuticals, medical devices, and healthtech. Current portfolio companies spread across China, Europe, and the United States.
Representative:
Shaoyu Chang, Vice President

 

Janssen: Janssen is committed to creating a future where disease is a thing of the past. The pharmaceutical companies of Johnson & Johnson are working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, immunology, infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Representative:
Herwig Janssen, VP, Licensing & Acquisitions Emerging Markets
Huadong Medicine Group: Huadong is a fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines. Founded in 1993, Huadong Medicine Group is now top 20 pharmaceutical companies in China with annual revenue of 4.5 billion USD.  Our products include API, chemical synthetic drugs, TCM and genetic engineering drugs that covers multiple therapeutic areas such as metabolic disease (diabetes), autoimmune disease, digestive disease, cardiovascular, oncology, and infectious disease. In recent years, Huadong Medicine Group has put great efforts on innovative new drug development, with multiple new drugs on our pipeline, we are expecting more collaborations and licensing opportunities to strengthen and expand our exciting pipeline.
Representatives:
Jianying Shi, Vice President
Xuan Peng, Director

Share Capital: Established in Shenzhen in 2007, is the earliest limited partnership professional venture capital institution in China. In the focus area, Share Capital deploys more entrepreneurial projects in the early and mid-stage, and then extend investment in companies with outstanding value to improve the overall return of the fund. Among them, the investment scope of Share Capital in the field of healthcare covers new drug research and development, biotechnology, innovative medical devices, medical and health services and other sub-areas, and formed a new drug research and development, biotechnology as a prominent feature of the investment portfolio.
Representative:
Tom Du, Medical Partner

Morningside Group: Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.
Representative:
Hongjian Zhang, Managing Director